Cooperative Agreement R43CK000494

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $476,453 Project Grant (R21AI178560) to Trustees of Boston University to develop intein-based tools for studying Ebola virus (EBOV) replication. The goals of this 2-year award, which runs from July 1, 2024 to May 31, 2026, are to leverage intein chemistry to create innovative technologies for EBOV research. Key objectives include: 1) Evaluating intein insertion site features to develop improved intein-based reporters for...

This federal Cooperative Agreement award, valued at $62,534,750.00, was granted by the National Institutes of Health (NIH) under the Advanced Research Projects Agency for Health (ARPA-H) program. The purpose of the award is to develop a broadly protective vaccine against emerging alphavirus infections, which can cause neurological and rheumatic diseases and pose substantial risks to human health. The key products and services to be delivered under this award include: Combining advanced...

This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to develop and test novel vaccine platforms against Kaposi's sarcoma-associated herpesvirus (KSHV) infection. The $1,979,806 award to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University supports two key objectives: Testing three different vaccine platforms targeting KSHV antigens, including recombinant measles virus (rMEV) and recombinant...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $280,769 to Abwiz Bio Inc. to develop neutralizing antibodies against Machupo virus, a New World arenavirus. The project aims to utilize advanced immunization techniques, a stabilized antigen, and high-throughput screening to identify and characterize antibodies that can target multiple epitopes on the virus...

The Department of the Army Medical Command awarded Invvax, Inc. a $1,878,970 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support research titled "Invariance Mapping of the Complete HBV Genome and Testing of MRE11 Repair Nuclease Toward the Improvement of CRISPR/Cas Therapy for Hepatitis B." The period of performance is from September 1, 2022 to August 31, 2026. Under this award, Invvax will conduct research to map the complete genome of...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $738,445 to Drexel University to develop a multivalent mRNA-based malaria vaccine. The key objectives are to: Optimize mRNA vaccine-induced antibody-mediated and cell-mediated protection against pre-erythrocytic stage Plasmodium falciparum parasites using a novel circumsporozoite protein (PfCSP) vaccine candidate....

This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $629,992.00 to Carogen Corp to test the safety and efficacy of CARG-201, an RNA replicon-based therapeutic vaccine for the treatment of chronic hepatitis B virus. The award period runs from September 1, 2024 to August 31, 2025. Carogen Corp, a minority-owned and small disadvantaged biopharmaceutical business, specializes in developing innovative...

This Cooperative Agreement award of $638,820 from the Defense Health Agency supports an mRNA multivalent approach to develop an innovative malaria vaccine. The project, funded through the Military Medical Research and Development program (CFDA 12.420), aims to broaden the immune targets against malaria infection by including both pre-erythrocytic-stage antigens and mosquito saliva antigens. The Geneva Foundation, a non-profit research organization, will conduct this research over a 3-year period...

The Flavivirus and Alphavirus REVAMPP (FLARE) Center, funded by a $46,715,173 Cooperative Agreement from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), is developing and optimizing protein nanoparticle, virion-based, and mRNA vaccine platforms, as well as monoclonal antibody-based treatments, to rapidly respond to emerging flaviviruses and alphaviruses with pandemic potential. The Center integrates the work of multiple academic...

This Cooperative Agreement award, with a total funding of $532,978.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective of the project is to study the tropism and cellular mechanisms of Ebola virus (EBOV) transmission from a pregnant mother to her fetus. The research aims to define the tropism of EBOV within placental tissues, investigate the role of phosphatidylserine...